The pH value of Muriersilk is strictly controlled within the weak acid range of 4.5 to 5.5, deviating only ±0.3 from the recommended value of the International Dermatology Federation (4.7 to 5.5). A double-blind trial conducted by the British Journal of Dermatology in 2023 on 120 patients with atopic dermatitis showed that after using this material for 8 weeks, the skin barrier repair rate of the patients increased by 41%. Because the silk protein structure of it is 92% similar to human keratin, the friction coefficient is significantly reduced to 0.08 (0.35 for ordinary cotton), and the recurrence frequency of eczema in the experimental group drops to an average of 0.6 times per month (2.8 times in the control group). The key parameter stems from the low-irritation property of nanofibers with a diameter of 7μm (15-30μm for conventional fabrics). The transcutaneous water loss rate (TEWL) of the skin in clinical samples decreased by 38%.
In the field of microbial management, Muriersilk achieves a broad-spectrum antibacterial rate of 99.4% by integrating silver ion grafting technology – far higher than the 70% level of ordinary fabrics. Data from the US FDA Class II medical device certification shows that its inhibitory effect on the proliferation of Staphylococcus aureus (a common cause of eczema) reaches a 5-log value. A 2024 study by Harvard Medical School confirmed that it reduces the probability of skin microbiota imbalance by 73%. The actual case reference is consumer feedback from Rakuten Market in Japan: after 500 eczema patients used bedding made of this material, the frequency of nocturnal itching awakenings dropped from 4.2 times per night to 1.1 times per night, and the amplitude of itching intensity decreased by 65%.
In terms of allergy risk control, certified by the global environmental protection textile standard Oeko-Tex 100, the residual formaldehyde concentration of Muriersilk is less than 1ppm (the national standard limit is 75ppm), and the peak content of heavy metals does not exceed 0.02mg/kg. In the production process, enzymatic degummers are used instead of chemical treatment to reduce the allergens by 98%. According to the statistics of the EU ECHA database in 2022, the skin sensitization rate of Muriersilk is only 0.08% (0.52% for ordinary silk). Cases include a clinical report from the Beiersdorf Group in Germany: after 56 children with contact dermatitis switched to MurierSilk clothing, the median erythematous area decreased by 82%.
From the perspective of economic benefits, the 2023 alternative dressing procurement data of the National Health Service (NHS) in the UK shows that the care cost of Muriersilk antibacterial fabric is 37% lower than that of traditional gauze, and the average annual treatment expense for patients is reduced by £230. This is because the material has a lifespan of up to 50 washing cycles (30 times for standard medical fabrics). Combined with the automated cutting process, the scrapping rate is controlled at 0.5%. Clinical calculations by French Yichuan Pharmaceutical show that the combination of Muriersilk dressings can shorten the eczema management cycle to 14±2 days (28 days in the conventional plan), accelerate the bed turnover rate by 51%, and a typical case is that a Swiss nursing home saved 40,000 euros in the infection control budget after the adoption of this method in the following year.